FDA Approves ViiV Healthcare's Epzicom
Epzicom is an antiviral medication.
It is in a group of human immunodeficiency virus (HIV) medicines called reverse transcriptase inhibitors. Epzicom helps keep the HIV virus from reproducing in the body.
Epzicom is used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). This medicine is not a cure for HIV or AIDS.
Epzicom is an HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs). Epzicom prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
Epzicom is marketed by ViiV Healthcare. It was approved by the U.S. Food and Drug Administration (FDA) for use by people living with HIV in August 2004.
Epzicom is a combination of two drugs: 600mg of Ziagen (abacavir) and 300mg of Epivir (lamivudine). Epzicom should be prescribed by a healthcare provider for patients who need both of these drugs. Both of these drugs can still be purchased individually for use in combination with other HIV drugs.
In the European Union, the single-tablet combination of Ziagen and Epivir is sold under the brand name Kivexa.
Epzicom must be combined with at least one other HIV drug, usually a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Epzicom is the brand name for a pharmaceutical treatment for HIV infection. It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen).
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by GlaxoSmithKline. It is also sold in other countries as Kivexa
Epzicom is a pill that contains two drugs used to fight HIV: abacavir (Ziagen) and Epivir (lamivudine, 3TC). Epzicom is manufactured by ViiV Healthcare. In Europe, it is called Kivexa. Generic versions have been tentatively approved under PEPFAR (see fact sheet 475.)
The drugs in Epzicom are called nucleoside analog reverse transcriptase inhibitors, or nukes. These drugs block the reverse transcriptase enzyme. This enzyme changes HIV’s genetic material (RNA) into the form of DNA. This has to occur before HIV’s genetic code gets inserted into an infected cell’s own genetic codes.